Individual drug monographs -- Appendixes: A. Selected new drugs:abametapir ; aducanumab-avwa ; afamelanotide ; anifrolumab-fnia ; asciminib ; atogepant ; avacopan ; avapritinib ; belumosudil ; belzutifan ; bempedoic acid ; brolucizumab-dbll ; difelikefalin ; dostarlimab-gxly - eculizumab ; efavirenz/emtricitabine/tenofovir ; elapegademase-ivir ; elbasvir/grazoprevir ; elexacaftor/tezacaftor/ivacaftor and ivacaftor ; emtricitabine/rilpivirine/tenofovir alafenamide ; enalapril/hydrochlorothiazide ; ephedrine ; factor IX, complex ; factor IX, human ; factor IX, recombinant ; finerenone ; fluocinolone ; fluocinonide ; lonapegsomatropin-tcgd ; loncastuximab tesirine-lpyl ; maribavir ; mobocertinib ; odevixibat ; ropeginterferon alfa-2b ; tisotumab vedotin-tfv ; vosoritide -- B. Ophthalmic, nasal, topical, and otic products -- C. Vaccines and toxoids -- D. Recent FDA drug approvals.
Summary:
Choose the drug handbook trusted by nurses for more than 35 years! Mosby's 2023 Nursing Drug Reference makes it easy to find the most vital information on the drugs you administer most frequently. More than 5,000 drugs are profiled -- including 35 new entries for drugs recently approved by the FDA. And no other drug guide places a higher emphasis on patient safety, with Black Box Warnings for dangerous adverse reactions, Safety Alerts for situations requiring special attention, and a focus on both common and life-threatening side effects. From nursing pharmacology expert Linda Skidmore-Roth, this perennial bestseller proves there is a difference in drug guides.
This resource is supported by the Institute of Museum and Library Services under the provisions of the Library Services and Technology Act as administered by State Library of Iowa.